Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Jazz Pharma Plc (JAZZ)

Jazz Pharma Plc (JAZZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer

PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announce that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the New Drug Application (NDA) seeking...

PHM : 46.69 (unch)
JAZZ : 140.85 (-0.76%)
Jazz Pharmaceuticals to Report 2019 Fourth Quarter and Full Year Financial Results on February 25, 2020

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 fourth quarter and full year financial results on Tuesday, February 25, 2020, after the close of the financial markets....

JAZZ : 140.85 (-0.76%)
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised)

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

NVS : 97.63 (-0.14%)
AVDL : 7.14 (+0.56%)
JAZZ : 140.85 (-0.76%)
TEVA : 12.22 (-2.78%)
Why Jazz (JAZZ) Could Beat Earnings Estimates Again

Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

JAZZ : 140.85 (-0.76%)
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

NVS : 97.63 (-0.14%)
AVDL : 7.14 (+0.56%)
JAZZ : 140.85 (-0.76%)
TEVA : 12.22 (-2.78%)
Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on January 21, 2020 seeking marketing approval for JZP-258,...

JAZZ : 140.85 (-0.76%)
PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period

PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announce that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended "HSR", with respect to the exclusive...

PHM : 46.69 (unch)
JAZZ : 140.85 (-0.76%)
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe

Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.

NVS : 97.63 (-0.14%)
AVDL : 7.14 (+0.56%)
JAZZ : 140.85 (-0.76%)
TEVA : 12.22 (-2.78%)
Jazz Pharmaceuticals Receives EU Marketing Authorisation for Sunosi® (solriamfetol) for Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission approved Sunosi® (solriamfetol) to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adults with...

JAZZ : 140.85 (-0.76%)
Plasminogen Activator Inhibitor 1, Pipeline Review, H2 2019 - Beam Therapeutics Inc, Jazz Pharmaceuticals Plc & MDI Therapeutics Inc - ResearchAndMarkets.com

The "Plasminogen Activator Inhibitor 1 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

JAZZ : 140.85 (-0.76%)
Jazz Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

JPM : 137.46 (-0.30%)
JAZZ : 140.85 (-0.76%)
JAZZ vs. ZTS: Which Stock Is the Better Value Option?

JAZZ vs. ZTS: Which Stock Is the Better Value Option?

JAZZ : 140.85 (-0.76%)
ZTS : 144.17 (-0.53%)
Jazz Enrolls First Patient in Phase II/III Leukemia Study

Jazz (JAZZ) begins enrollment in the phase II/III study evaluating JZP-458 for treating pediatric and adult patients with acute lymphoblastic leukemia, hypersensitive to E. coli-derived asparaginases

INVA : 15.07 (+0.80%)
JAZZ : 140.85 (-0.76%)
ACRX : 1.60 (-4.19%)
GH : 84.30 (+3.06%)
Zacks.com featured highlights include: Lithia Motors, Marathon Petroleum, Meritage Homes, Jazz Pharmaceuticals and Barclays PLC

Zacks.com featured highlights include: Lithia Motors, Marathon Petroleum, Meritage Homes, Jazz Pharmaceuticals and Barclays PLC

LAD : 131.00 (+0.10%)
BCS : 9.08 (-0.77%)
MTH : 72.19 (-0.96%)
JAZZ : 140.85 (-0.76%)
MPC : 58.33 (-1.97%)
7 Impressive Growth Stocks to Buy for 2020

The prospects of growth stocks appear bright for 2020, making the following companies attractive bets.

MCO : 277.83 (+1.86%)
VEEV : 158.87 (+3.20%)
JAZZ : 140.85 (-0.76%)
LHCG : 158.11 (-0.37%)
AMED : 197.88 (-1.56%)
ALGN : 274.95 (+0.73%)
MA : 340.95 (+1.52%)
Are Investors Undervaluing Jazz Pharmaceuticals (JAZZ) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

JAZZ : 140.85 (-0.76%)
5 High Earnings Yield Stocks for a Standout Portfolio

If you are not sure whether to invest your money in bonds or stocks, a key parameter that can show you the right direction is earnings yield.

LAD : 131.00 (+0.10%)
BCS : 9.08 (-0.77%)
MTH : 72.19 (-0.96%)
JAZZ : 140.85 (-0.76%)
MPC : 58.33 (-1.97%)
Jazz Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 2/3 Study Evaluating JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in the pivotal Phase 2/3 clinical study for JZP-458, a recombinant Erwinia asparaginase molecule that uses...

JAZZ : 140.85 (-0.76%)
Create a Value-Based Portfolio With These 4 Low P/CF Stocks

Investing in stocks based on value analysis is generally considered one of the best practices. In value investing, investors pick stocks that are usually cheap but fundamentally sound.

CYOU : 10.68 (-0.09%)
PWR : 40.50 (-0.74%)
ALXN : 102.56 (-0.83%)
JAZZ : 140.85 (-0.76%)
Is Jazz Pharmaceuticals (JAZZ) Outperforming Other Medical Stocks This Year?

Is (JAZZ) Outperforming Other Medical Stocks This Year?

JAZZ : 140.85 (-0.76%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS +0.89 , SEDG +0.05 , THC -0.57 , TER -2.42 , LITE -3.44
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar